Toxicity profile grade 3 or higher during treatment
| AE, n (%) . | Sequential (n = 118) . | Alternating (n = 115) . | P . |
|---|---|---|---|
| Hematologic toxicity | |||
| Anemia | 4 (3) | 4 (3) | 1.0 |
| Neutropenia | 22 (19) | 26 (22) | .3 |
| Thrombocytopenia | 25 (21) | 23 (20) | .2 |
| Nonhematologic toxicity | |||
| Gastrointestinal toxicity | 7 (6) | 7 (6) | 1.0 |
| Infections | 7 (6) | 8 (7) | .9 |
| Peripheral neuropathy | 5 (4) | 3 (3) | .7 |
| DVT/thromboembolism | 5 (3) | 3 (3) | .5 |
| Skin rash | 6 (5) | 5 (4) | .8 |
| AE, n (%) . | Sequential (n = 118) . | Alternating (n = 115) . | P . |
|---|---|---|---|
| Hematologic toxicity | |||
| Anemia | 4 (3) | 4 (3) | 1.0 |
| Neutropenia | 22 (19) | 26 (22) | .3 |
| Thrombocytopenia | 25 (21) | 23 (20) | .2 |
| Nonhematologic toxicity | |||
| Gastrointestinal toxicity | 7 (6) | 7 (6) | 1.0 |
| Infections | 7 (6) | 8 (7) | .9 |
| Peripheral neuropathy | 5 (4) | 3 (3) | .7 |
| DVT/thromboembolism | 5 (3) | 3 (3) | .5 |
| Skin rash | 6 (5) | 5 (4) | .8 |
DVT, deep venous thrombosis.